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    A total of 28 patients with urogenitai tract cancers ．．． 17 non－seminomatous testicular cancers，
4 urinary bladder cancers， 1 renal pelvic cancer， and 1 penile cancer were treated with CDDP only
or three－drug combinatien consisting of’bDDP， vinblastine， and bleoinycin．
    On the CDDP single therapy， platinum was given in 4 dosage of 25 mg／body as 2－hour intravenous
infusion for 5 consecutive days in a week for 3 weeks． This treatment unit was repeated for 3 times．
    On the CDDP combination therapy， platinum was given in the same manner as the therapy
with single CDDP， and vinblastine was given on the first and second days of 5 consecutive days in
a week in a dosqge of 10 mg／body for 3 weeks for 4 courses and then given as a single injection in a
dosage of 10’高〟^body for 4 weeks． This tre4tment was applied on and off for 2 years．
   Bleomycin was given weekly．f（）r l 2 weeks in a dosage of 30皿g／body by intravenous injection．
   Threc disseminated testicular cancers and one renal pelvic ．cancer were treated with CDDP．
The therapy with CDDP single was not sio effec’狽奄魔?for testicular cancers but a tumor regression was
observed endoscopically in renal pelvic cancer．
   F6粛t66h．．d五s66血inat6d．．te9亡icular ca漉ers，4urinary bladdbr cancers， and l penile cahcer were
treated with ’CDDP， vinblastine， ahd bleomycin given in combination．
   Two ofthe’ 14 testicular’eancers （140／．．） achieved complete response and 5 of the 14 （360／．） achieved
partial response． But the 3－drug combination therapy was not so effective for urinary bladder cancer
and penile cancer．
   On the toxicity of CDDP， the CDDP caused moderate to severe nausea and vomiting in almost
6f all patients during 5 days of treatment． ’None of these patients treated with CDDP showed pgphro－
toxity and ototQXity． But in the CDDP cornbination therapy， the most serious side effect is the myeJo－
suppression dUe tO vinblastine． LeukoPenia （below 1，000／rnm3） was observed in 5 of 19 patients．
   We believe the CDDP－combination therapy represents a great advance in the management of



























腫瘍1例である （Table l）． CDDP単独療法は，


































皿 治 療 成 績
膀 胱 腫 瘍
腎 孟 腫 瘍






































Na 年齢 性 疾 患 Stage投与方法 投与量 縮少率（％）合器前田囲転帰離
1 26 ♂ 睾丸腫瘍（E，S）※皿b
2 33 ♂ 睾丸腫瘍（T） 皿b
3 21 ♂ 睾丸腫瘍（E，C，T）Ha
4 27 ♂ 睾丸腫瘍（E，S） 皿b
5 25 ♂ 睾丸腫瘍（E）
6 30 ♂ 睾丸腫瘍（E）
皿b
Nb
7 44 ♂ 睾丸腫瘍（E，S） 且a
8 34 ♂ 睾丸腫瘍（E）
9 32 ♂ 睾丸腫瘍（E）
10 27 ♂ 睾丸腫瘍（E）





12 45 ♂ 睾丸腫瘍（E，T） lla








































































































































































あった．すなわち睾丸腫瘍14例（stage Ila 5例， IIb

















 進行膀胱腫瘍（stage－C 1例， stage－D 3例）に対
してはCDDP併用療法でも抗腫瘍効果は低く，1
例はCDDP I 25 mg（25 mg／day）投与後，1例は































































19 （ 100 ％）
19 （ 100 ％）






















































































CDDP施行前睾丸腫瘍組織            CDDP施行後摘出頸部腫瘍組織
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